# Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

> **NCT07677813** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ou Bai, MD/PHD** · enrollment: 66 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** R-CHOP+Orelabrutinib
- **DRUG:** POLA-R-CHP+orelabrutinib
- **DRUG:** R-miniCHOP +orelabrutinib
- **DRUG:** Zuberitamab-CHOP+orelabrutinib
- **DRUG:** POLA-Hi-CHP+orelabrutinib
- **DRUG:** Hi-miniCHOP +orelabrutinib
- **DRUG:** RMTO
- **DRUG:** HiMTO
- **DRUG:** Pola-R-miniCHP+O
- **DRUG:** Pola-Hi-miniCHP

## Key facts

- **NCT ID:** NCT07677813
- **Lead sponsor:** Ou Bai, MD/PHD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-16
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677813, "Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*